

Full Title: State-dependent alterations in CSF Abeta42 levels in cognitively-intact elderly with late life major depression

Short Title: State-dependent alterations in CSF Abeta42

Authors: Nunzio Pomara, Davide Bruno, Ricardo Osorio, Chelsea Reichert, Jay Nierenberg, Antero S. Sarreal, Raymundo T. Hernando, Charlie Marmar, Henrik Zetterberg, and Kaj Blennow

Key Words: Late-life Major Depression, Abeta42, Elderly, Alzheimer's disease

Correspondence:

Nunzio Pomara, MD

Nathan S. Kline Institute

140 Old Orangeburg Rd., Orangeburg, NY 10962

Pomara@nki.rfmh.org

Statement of Conflicts: None Declared

Regarding affiliations, our hospital wants us to list both the academic and hospital affiliations. So for me and Kaj they are:

1. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
2. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Additionally, I (HZ) have the following address:

Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK

Abstract

Depression has been linked to Alzheimer's disease (AD) as either an increased risk factor for its development or as a prodromal symptom. The neurobiological basis for such association, however, remains poorly understood. Numerous studies have examined whether changes in amyloid beta ($A\beta$) metabolism, which has been implicated in AD, are also found in depression. In this paper, we investigated the relationship between depressive symptoms and cerebrospinal fluid (CSF) $A\beta$ indices, in healthy cognitively normal elderly with late-life major depression (LLMD) and controls, by using a longitudinal approach, which is a novel contribution to the literature. Significantly lower levels of CSF $A\beta_{42}$ were observed in the LLMD group at baseline and were associated with more depressive symptoms. During the longitudinal follow up, the depressed group remained cognitively unchanged, but was significantly less depressed than at baseline. A greater improvement in depressive symptoms was associated with increases in CSF $A\beta_{42}$ levels in both groups. Increases in CSF $A\beta_{42}$ and $A\beta_{40}$ were also associated with increased CSF total tau. Our results suggest that LLMD may be associated with state-dependent effects of CSF $A\beta_{42}$ levels. Future studies should determine if the association reflects state-dependent changes in neuronal activity in depression.

Introduction

Several lines of evidence from epidemiological, case-control and longitudinal studies provide support for an association between depression or depressive symptoms, and an increased risk for dementia and Alzheimer's disease (AD), or for depression as a prodromal state of AD (Jorm, 2001; Osorio, Gumb, & Pomara, 2014). This relationship has been described not only for late onset depression, but also for depression starting earlier in life (Byers & Yaffe, 2011). In a longitudinal study conducted by Wilson and colleagues (2002) in cognitively normal elderly, increases in the number of depressive symptoms at baseline were associated with a 19% increased risk of AD, on average, during a 7-year longitudinal follow-up period. Yet puzzlingly there have also been results that do not support such an association (Beck et al., 2009; Richard et al., 2013), thereby highlighting the possible etiological heterogeneity of depression with respect to its association with AD, and the need for further study.

Although the neurobiological mechanisms underlying the association between AD and depression are not yet clear, it is possible that there may be a common disturbance in Amyloid Beta ($A\beta$) metabolism (Pomara and Doraiswamy, 2003) in both conditions. Studies conducted by our group and others (Pomara et al., 2006; 2012) have highlighted abnormalities in $A\beta_{40}$ or $A\beta_{42}$ levels or their ratios, in plasma or serum, in individuals with depression. Analogously, a relatively smaller number of investigations have also reported changes in cerebrospinal fluid (CSF) $A\beta$ concentration or brain amyloid burden using PET imaging in individuals with depression or depressive symptoms, albeit with conflicting results (e.g. Dinniz, Teizeira, Machado-Vieira, Talib, Radanovic, Gattaz, & Forlenza, 2014; Gudmundsson, Skoog, Waern, Blennow, Palsson, Rosengren, & Gustafson, 2007; Madsen et al., 2012; Pomara et al., 2012; Yasuno et al., 2016).

Methodological differences, however, may be at the root of these differences in results, including heterogeneity in the studied populations, including sometimes presence of individuals with

MCI(Abbasowa & Heegaard, 2014; do Nascimento, Silva, Malloy-Diniz, Butters, & Diniz, 2015; Harrington, Lim, Gould, & Maruff, 2015; Osorio, Gumb, & Pomara, 2014). A separate issue pertains to the use of different approaches for detecting depression, with most relying on patients' self-ratings, which may lack diagnostic specificity, and only a few studies employing structured interviews based on DSM diagnostic criteria. Finally, and critically, standardized pre-analytical and laboratory procedures for quantifying A β across centers were not employed (Abbasowa & Heegaard, 2014). All of the existing studies have been limited to cross sectional comparisons based on a single A β determination; thus, it is not known if these abnormalities persist over time.

To address these limitations, we conducted a longitudinal prospective study in depressed elderly and age-matched controls, all of whom were cognitively normal at baseline. All subjects were diagnosed using a structured interview as per DSM-4 criteria, and the same lab and immunoassay method with demonstrated sensitivity and reliability for A β determination was employed (see Methods). Our goal was to determine first whether LLMD and time (baseline to follow-up) had an effect on the A β levels; and second to determine whether any time-related change in A β was associated with changes in the severity of depressive symptoms. Additionally, analogous analyses were also carried out on CSF total-tau and p-tau to gauge the possible emergence of neurodegeneration and neurofibrillary pathology, respectively, in the course of the longitudinal study.

Methods

This study was conducted in accordance with the Declaration of Helsinki. Approval for this study was received from the Nathan S. Kline Institute/Rockland Psychiatry Center Institutional Review Board (NKI/RPC IRB) and the NYU Langone Medical Center Institutional Review Board. All participants provided written informed consent before their participation. Ninety-one participants, aged 60 years and older, with an MMSE score of at least 28, completed a 3-year longitudinal study. At baseline, 51 of these

individuals agreed to an optional lumbar puncture (LP). Three of these individuals were excluded for MRI findings, and an additional individual was excluded for an MMSE score below 28 (*Table 1*).

Table 1. Baseline demographics of cognitively intact individuals with LLMD and aged-matched control subjects.

	Baseline (Mean(<i>SD</i>))		Statistical Analysis		
	Control Group (N=19)	LLMD Group (N=28)	t	df	p
Age	68.1 (7.3)	66.5 (5.4)	0.84	45	0.41
Education	16.7 (2.7)	16.5 (2.7)	0.27	44	0.79
HAM-D Score	1.2 (1.9)	14.9 (8.8)	8.02	45	<.0001*
MMSE Score	29.5 (0.5)	29.8 (0.6)	1.56	45	0.13

CSF was obtained from 47 individuals (see *Table 2*), with late-life major depression group (LLMD; N=28) and age- and gender-matched control group (N=19), and again at the 3-year follow-up visit (LLMD group, N=19; control group, N=17). The analyses are limited to the follow-up group. CSF levels of A β 42, A β 40, total-tau (t-Tau) and p-tau were measured using previously established methods by board-certified laboratory technicians who were blinded to clinical data (Pomara et al. 2012). Participants underwent a comprehensive neuropsychological evaluation as well as a clinical evaluation that included the Hamilton Depression scale (HAM-D), at baseline and at follow-up. Pearson's correlations were computed between A β indices and HAM-D scores. All statistical analysis was performed using SPSS statistical software package, version 22.0 for Windows (SPSS, Inc., Chicago).


Table 2. HAM-D and CSF levels of A β 42, A β 40, total-tau (t-Tau) and p-tau at baseline and follow-up.

	LLMD		Controls	
	Baseline Mean (<i>SD</i>)	Follow-Up Mean (<i>SD</i>)	Baseline Mean (<i>SD</i>)	Follow-up Mean (<i>SD</i>)
HAM-D	14.9 (8.8)	8.74 (8.1)	1.2 (1.9)	2.24 (6.01)
CSF Aβ42	231.42 (117.64)	261.05 (148.01)	335.94 (187.71)	279.29 (118.17)
CSF Aβ40	5285.84 (2408.60)	3728.47 (1379.17)	6550.29 (2799.71)	4020.06 (1145.78)
T-tau	254.33 (122.39)	277.33 (111.98)	343.59 (152.59)	365.71 (136.17)
P-tau	48.68 (30.76)	49.63 (34.86)	48.93 (25.87)	51.12 (18.12)

Results

To evaluate if clinical group (LLMD and control) and time had an effect on the A β levels, we conducted two 2x2 repeated measures ANOVAs (GROUP, between-subjects; and TIME, within-subjects) on A β 40 and A β 42. A main effect of time was detected on A β 40, $p < .001$, showing a decline in levels between baseline (5882.94, SD=2631.67) and follow-up (3866.17, SD=1264.98); no main effect of LLMD ($p = .202$) or an interaction were observed ($p = .146$). When we examined A β 42, in contrast, we found a significant interaction ($p = .050$), suggesting that although depressed individuals had lower levels at baseline, this difference was not present at follow-up (see *Figure 1*).

Figure 1. Three year follow-up of cognitively intact individuals with LLMD and control subjects. a) HAM-D scores in the LLMD group and control subjects at baseline and 3-year follow-up. There was a significant decrease in HAM-D score in the LLMD group at the 3-year follow-up as previously reported in Hashimoto et al. (2011). b) CSF A β 42 levels in the LLMD group and control subjects at baseline and 3-year follow-up. There was a significant interaction between A β 42 levels and time.



To evaluate whether changes in A β were linked with changes in the severity of depressive symptoms, we carried out Pearson's bivariate correlations between A β and Ham-D levels, using change in Ham-D scores and change in CSF A β concentration (follow-up – baseline). The reductions in depressive symptoms observed over time were significantly correlated with increases in CSF A β 42 levels, both in the entire cohort ($r = -.451, p = .006$) and within the LLMD group ($r = -.547, p = .015$), specifically, but not in the control group ($p = .809$). The same relationship was not significant with A β 40 (p 's $> .200$).

To examine whether changes in A β 42 were related to t-tau and p-tau, Pearson's bivariate correlations were conducted between change scores in the LLMD group, as referenced above. Comparisons of the follow-up to baseline levels, revealed a significant correlation between CSF A β 42

levels and T-Tau ($r=.557, p=.016$). A significant correlation was found with CSF A β 40 levels as well ($r=.586, p=.011$). Thus, increases t-tau in the LLMD group, over time, were associated with increases in both CSF A β 42 and CSF A β 40. The same significant correlations were not found between p-tau and CSF A β 42 or CSF A β 40 (p 's $>.700$).

Discussion

This is the first prospective longitudinal study to have examined the relationship between different phases of depression and CSF A β indices in cognitively intact elderly. Participants were examined at baseline who either had LLMD or were controls, and CSF A β 42 and A β 40 levels were found to be lower in this depressed group compared to controls (Pomara et al., 2012). Over the 3-year longitudinal study, we observed that the depressed group became significantly less depressed than at baseline. At the same time, we also noted that the difference in CSF A β levels between groups was no longer significant. Consistently with this finding, we observed that the degree of change in the severity of depression in all participants over the life of the study was correlated with change in A β 42. All in all, these findings suggest the possibility of a state-dependent association between CSF A β levels, especially A β 42, and depressive symptoms. This would indicate that the metabolic disturbances leading to A β abnormalities in LLMD individuals are reversible rather than fixed, and possibly treatable.

Additionally, the possibility that the numerical increase in soluble CSF A β 42 level, which we observed in the MDD group, emerged in the presence of increased brain amyloid burden cannot be excluded since CSF A β 42 levels in the depressed group were still numerically lower than in controls at year three.

We also found that increases in CSF A β 42 and A β 40 from baseline during the 3-year longitudinal follow-up were associated with increases in t-tau. Increases in tau have been associated with progressive cognitive decline and AD, and have been ascribed to increase neuronal and axonal degeneration. However, the correlations with tau in this study were not associated with progressive cognitive decline or the emergence of AD and the increases remained within the normal range of CSF t-tau concentrations. This raises the possibility that other factors may have contributed to this relationship. Several lines of

evidence from preclinical studies suggest that increased neuronal activity can result in increased release of A β peptides as well as tau (Yamanda et al., 2014). Thus, these results are consistent with the hypothesis that state-dependent changes in neuronal activity may underlie the aforementioned association.

Results from recent investigations of resting fMRI connectivity in depression suggest a complex pattern of neuronal activity in LLMD with reductions in brain functional connectivity in the cognitive network as well as increases in the default mode network (DMN) (Kenny, O'Brien, Cousins, Richardson, Thomas, Firbank, & Blamire, 2010). However, resting fMRI connectivity studies in individuals with late-life depression, which are most pertinent to this report, have consistently described reductions in the default mode network connectivity (Wu et al. 2011, Alexopoulos et al. 2012). Human studies using CBF and FDG-PET report reductions in cortical neuronal activity in the depressive phase of unipolar depression and improvement with remission (Nikolaus, Larisch, Vosberg, & Muller-Gartner, 2000). These results are consistent with our hypothesis that state-dependent effects on neuronal activity may underlie the changes in CSF A β 42 across different phases of depression.

However, alternative hypotheses should be considered for the association between CSF A β 42 and depressive symptoms including the possibility of state-dependent changes in oligomeric forms of A β in depression. These forms might have escaped detection by the electrochemiluminescence technology assay that we employed, as was previously reported for the ELISA method (Englund et al., 2009; Stehn et al., 2005), and they may have also masked epitopes of A β 42 and A β 40, resulting in their low levels. Thus increases in oligomeric forms of A β might have contributed to the low levels of CSF plasma A β 42 and A β 40 observed at baseline and to their association with more depressive symptoms. Conversely, their reduction during the longitudinal period was associated with higher CSF A β 42 levels and reduced depression.

Thus future studies should also examine oligomeric forms of CSF A β in elderly depressives. Additionally, since none of the existing investigations simultaneously determined brain amyloid burden by PET or CSF A β and tau levels, future studies should therefore also

examine the relationship between these AD biomarkers and measures of neuronal and functional connectivity in elderly depressives, both in the depressive phase of the illness and following remission.

There is also emerging evidence that changes in the quality of sleep and its architecture, which are commonly disrupted in depression, can result in increased brain amyloid burden through effects in neuronal activity and glymphatic clearance. However, so far none of these studies have been conducted in depression. Thus it will important for future studies to determine if these factors contribute to altered A β dynamics in elderly depressives.

References

- Abbasowa, L., & Heegaard, N. H. (2014). A systematic review of amyloid- β peptides as putative mediators of the association between affective disorders and Alzheimer' s disease. *Journal of affective disorders*, 168, 167-183.
- Becker, J. T., Chang, Y. F., Lopez, O. L., Dew, M. A., Sweet, R. A., Barnes, D., ... & Reynolds, C. F. (2009). Depressed mood is not a risk factor for incident dementia in a community-based cohort. *The American Journal of Geriatric Psychiatry*, 17(8), 653-663.
- Byers, A. L., & Yaffe, K. (2011). Depression and risk of developing dementia. *Nature Reviews Neurology*, 7(6), 323-331.
- Diniz, B. S., Teixeira, A. L., Machado-Vieira, R., Talib, L. L., Radanovic, M., Gattaz, W. F., & Forlenza, O. V. (2014). Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. *The Journals of Gerontology Series B: Psychological Sciences and Social Sciences*, 69(6), 845-851.
- do Nascimento, K. K. F., Silva, K. P., Malloy-Diniz, L. F., Butters, M. A., & Diniz, B. S. (2015). Plasma and cerebrospinal fluid amyloid- β levels in late-life depression: A systematic review and meta-analysis. *Journal of psychiatric research*, 69, 35-41.
- Gudmundsson, P., Skoog, I., Waern, M., Blennow, K., Pálsson, S., Rosengren, L., & Gustafson, D. (2007). The relationship between cerebrospinal fluid biomarkers and depression in elderly women. *The American journal of geriatric psychiatry*, 15(10), 832-838.
- Harrington, K. D., Lim, Y. Y., Gould, E., & Maruff, P. (2015). Amyloid-beta and depression in healthy older adults: A systematic review. *Australian and New Zealand Journal of Psychiatry*, 49(1), 36-46.
- Hashimoto, K., Bruno, D., Nierenberg, J., Marmar, C. R., Zetterberg, H., Blennow, K., & Pomara, N. (2016). Abnormality in glutamine–glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. *Translational psychiatry*, 6(3), e744.
- Jorm, A. F. (2001). History of depression as a risk factor for dementia: an updated review. *Australian and New Zealand Journal of Psychiatry*, 35(6), 776-781.
- Kenny, E. R., O'Brien, J. T., Cousins, D. A., Richardson, J., Thomas, A. J., Firbank, M. J., & Blamire, A. M. (2010). Functional connectivity in late-life depression using resting-state functional magnetic resonance imaging. *The American Journal of Geriatric Psychiatry*, 18(7), 643-651.
- Madsen, K., Hasselbalch, B. J., Frederiksen, K. S., Haahr, M. E., Gade, A., Law, I., ... & Hasselbalch, S. G. (2012). Lack of association between prior depressive episodes and cerebral [11 C] PiB binding. *Neurobiology of aging*, 33(10), 2334-2342.

Nikolaus, S., Larisch, R., Beu, M., Vosberg, H., & MÜLLER-GÄRTNER, H. W. (2000). Diffuse cortical reduction of neuronal activity in unipolar major depression: a retrospective analysis of 337 patients and 321 controls. *Nuclear medicine communications*, 21(12), 1119-1125.

Osorio, R. S., Gumb, T., & Pomara, N. (2014). Soluble Amyloid- β Levels and Late-Life Depression. *Current pharmaceutical design*, 20(15), 2547.

Pomara, N., Bruno, D., Sarreal, A. S., Hernando, R. T., Nierenberg, J., Petkova, E., ... & Zetterberg, H. (2012). Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. *American Journal of Psychiatry*.

Pomara, N., & Doraiswamy, P. M. (2003). Does increased platelet release of A β peptide contribute to brain abnormalities in individuals with depression?. *Medical hypotheses*, 60(5), 640-643.

Pomara, N., Doraiswamy, P. M., Willoughby, L. M., Roth, A. E., Mulsant, B. H., Sidsis, J. J., ... & Pollock, B. G. (2006). Elevation in plasma A β 42 in geriatric depression: a pilot study. *Neurochemical research*, 31(3), 341-349.

Richard, E., Reitz, C., Honig, L. H., Schupf, N., Tang, M. X., Manly, J. J., ... & Luchsinger, J. A. (2013). Late-life depression, mild cognitive impairment, and dementia. *JAMA neurology*, 70(3), 383-389.

Tateno, A., Sakayori, T., Higuchi, M., Suhara, T., Ishihara, K., Kumita, S., ... & Okubo, Y. (2015). Amyloid imaging with [18F] florbetapir in geriatric depression: early-onset versus late-onset. *International journal of geriatric psychiatry*, 30(7), 720-728.

Wilson, R. S., Boyle, P. A., Capuano, A. W., Shah, R. C., Hoganson, G. M., Nag, S., & Bennett, D. A. (2015). Late-Life Depression Is Not Associated With Dementia-Related Pathology.

Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., ... & Holtzman, D. M. (2014). Neuronal activity regulates extracellular tau in vivo. *The Journal of experimental medicine*, 211(3), 387-393.

Yasuno, F., Kazui, H., Morita, N., Kajimoto, K., Ihara, M., Taguchi, A., ... & Iida, H. (2016). High amyloid- β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. *International journal of geriatric psychiatry*.